Inalimarev
- Generic Name
- Inalimarev
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 685563-13-7
- Unique Ingredient Identifier
- -
- Associated Conditions
- -
- Associated Therapies
- -
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2008-04-30
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 18
- Registration Number
- NCT00669734
- Locations
- 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath